Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.61 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15592354 | 0.89 | TP53BP1 (0.61) | TP53BP1KAT6AKMT2APSMB8PSMB5 | |
| SCHEMBL104557 | 0.82 | TP53BP1 (0.67) | TP53BP1KAT6AKMT2APSMB8PSMB5 | |
| SCHEMBL30277616 | 0.82 | TP53BP1 (0.67) | TP53BP1KAT6AKMT2APSMB8PSMB5 | |
| SCHEMBL21345718 | 0.82 | TP53BP1 (0.67) | TP53BP1KAT6AKMT2APSMB8PSMB5 | |
| SCHEMBL11994348 | 0.81 | TP53BP1 (0.65) | TP53BP1KAT6AKMT2APSMB8PSMB5 | |
| SCHEMBL19755858 | 0.81 | SMN1; SMN2 (0.54) | KMT2AGAAHSD17B10MEN1SMN1; SMN2 | |
| SCHEMBL18049985 | 0.81 | SMN1; SMN2 (0.54) | KMT2AGAAHSD17B10MEN1SMN1; SMN2 | |
| SCHEMBL12305721 | 0.80 | TP53BP1 (0.64) | TP53BP1KAT6AKMT2APSMB8PSMB5 | |
| SCHEMBL20646759 | 0.80 | TP53BP1 (0.64) | TP53BP1KAT6AKMT2AGAAHSD17B10 | |
| SCHEMBL30277542 | 0.79 | TP53BP1 (0.62) | TP53BP1KAT6AKMT2AGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TP53BP1 3916/4885KAT6A 2397/4885KMT2A 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.